Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ziprasidone (Geodon) Clear all
Terminated Phase 4 Interventional Results available

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

NCT01844700
View directory record Official record
Conditions
High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions
Ziprasidone, aripiprazole, quetiapine, or risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

NCT00340379
View directory record Official record
Conditions
Affective Disorders
Interventions
Ziprasidone, Sertraline, Haloperidol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions

NCT01581866
View directory record Official record
Conditions
Healthy
Interventions
Ziprasidone Hydrochloride
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions

NCT01581879
View directory record Official record
Conditions
Healthy
Interventions
Ziprasidone Hydrochloride
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 4 Interventional

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
San Bernardino, California • ‘Aiea, Hawaii • Schaumburg, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2009 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 25, 2026, 5:45 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 25, 2026, 5:45 AM EDT
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 5:45 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 25, 2026, 5:45 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 5:45 AM EDT
Completed No phase listed Observational

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

NCT04002700
View directory record Official record
Conditions
Stroke
Interventions
Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,234,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 25, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)

NCT01293825
View directory record Official record
Conditions
Medication Adherence, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

NCT00406315
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
28
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

NCT01006551
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

NCT00821444
View directory record Official record
Conditions
Healthy
Interventions
ziprasidone, B16 Fasted, B16 Fed
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 5:45 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade

NCT00225498
View directory record Official record
Conditions
Schizophrenia
Interventions
ziprasidone vs risperidone or olanzapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 25, 2026, 5:45 AM EDT